Bristol-Myers: Phase 3 Study Of Opdivo Plus Yervoy Met Co-primary Endpoint

Bristol-Myers Squibb Co. (BMY) said that a Phase 3 study evaluating Opdivo plus Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma or RCC met its co-primary endpoint, demonstrating superior overall survival or OS compared to sunitinib in intermediate- and poor-risk patients.

from RTT - Biotech http://ift.tt/2vONkol
via IFTTT